
Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target
Aurinia Pharmaceuticals (AUPH) Analyst Ratings
Bulls say
Aurinia Pharmaceuticals is projected to experience substantial revenue growth, with risk-adjusted product revenues expected to rise from $243.7 million in 2025 to $932.3 million by 2033. The anticipated launch of aritinercept is forecasted to generate risk-adjusted revenue of $15.4 million in 2030, increasing significantly to $281.6 million by 2033, assuming a 20% probability of launch and a 15% peak penetration rate. Furthermore, the upcoming 2024 ACR LN guideline is expected to materially enhance the market position of LUPKYNIS, catalyzing a new phase of growth for the product starting in 2027.
Bears say
Aurinia Pharmaceuticals faces challenges due to limited therapeutic options and high competition within the autoimmune disease treatment market, impacting its revenue growth potential. Additionally, the company's reliance on a single product, LUPKYNIS, raises concerns regarding sustainability and market penetration, especially as it faces upcoming patent expirations. Lastly, the development pipeline, including AUR200, may not sufficiently mitigate risks associated with dependency on existing products or lead to timely commercial success.
This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares